Non-Hodgkin’s Lymphoma (NHL) is the most common type of lymphoma. Hodgkin’s lymphoma is less common, and has a slightly higher cure rate. According to SEER data, in 2011 there were 530,919 people living with NHL in the United States. There has been a 73 percent rise between 1973 and 1991 in NHL with continued increases ever since.
Approximately 2.1 percent of men and women will be diagnosed with non-Hodgkin lymphoma at some point during their lifetime, based on 2008-2010 SEER data, and the 5 year survival rate is 69.3%.
The survival rate for lymphoma has greatly increased in the past 40 years, especially in children. The five-year relative survival rate for NHL patients has risen from 31 percent in Caucasians from 1960 to 1963 to 71.2 percent for all races from 2003 to 2009. In youths under 20, the 5 year survival rate is 84.5%, which is a significant improvement since most youths did not survive 5 years in the 1970s. NHL and Hodgkin lymphoma account for 11% of total cancer diagnoses in children.
Some of the many subtypes of NHL include: B cell and T cell types , follicular lymphoma, cutaneous lymphoma, marginal zone lymphoma, mantle cell lymphoma, Burkitt’s lymphoma, and lymphoblastic lymphoma . Lymphoplasmacytic lymphoma is a related lymphoma also known as Waldenstrom’s macroglobulinemia. Other lymphomas may be named for their site of presentation, such as CNS lymphoma.
A number of risk factors are known to be associated with lymphoma. Among the most well-established risk factors include:
Other risk factors include:
A biopsy of the swollen lymph node (s) is recommended and is often preceded by imaging of the body part affected, which can include x-ray, ultrasound, positron emission tomography (PET) computed tomography (CT) or MRI. Once the disease has been detected, other testing of the cancer cells includes cytogenetics and flow cytometry, as well as PET/CT.
Blood testing assesses white and red blood cells (RBC, CBC) and liver function are also routinely part of the diagnosis and monitoring of lymphomas
Multiple nutritional supplements have been associated with reduced cancer incidence and/or cancer progression. The list below contains those with the greatest evidence-base and benefit, though it is not necessary that they all be included.
 Jaglowski SM1, Linden E, et al. Lymphoma in adolescents and young adults. Semin Oncol. 2009 Oct;36(5):381-418. doi: 10.1053/j.seminoncol.2009.07.009.
 Talamini R, Polesel J, Montella M, Maso LD, Crispo A, Spina M, Franceschi S, Crovatto M, La Vecchia C. Smoking and non-Hodgkin lymphoma: case-control study in Italy. Int J Cancer. 2005 Jul 1;115(4):606-10.
 Wu XC, Andrews P, Chen VW, Groves FD. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol. 2009 Nov;33(5):337-46.
 Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014 Mar 27;28(6):881-90.
 Leo QJ, Ollberding NJ, Wilkens LR, Kolonel LN, Henderson BE, Le Marchand L, Maskarinec G. Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: the Multiethnic Cohort study. Cancer Causes Control. 2014 Jul 29.
 Salem EA, Hegazy MM, El Khouley EA. Pesticide exposure as a risk factor for lymphoproliferative disorders in adults. East Mediterr Health J. 2014 Jun 18;20(6):363-71.
 Pahwa M, Beane Freeman L, Spinelli JJ, Blair A, Pahwa P, Dosman JA, McLaughlin JR, Demers PA, Hoar Zahm S, Cantor KP, Weisenburger DD, Harris SA. 0409 The North American Pooled Project (NAPP): Pooled analyses of case-control studies of pesticides and agricultural exposures, lymphohematopoietic cancers and sarcoma. Occup Environ Med. 2014 Jun;71 Suppl 1:A116.
 Schinasi L, Leon ME. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. Int J Environ Res Public Health. 2014 Apr 23;11(4):4449-527.
 Eriksson M, Hardell L, Carlberg M, Akerman M. Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. Int J Cancer. 2008 Oct 1;123(7):1657-63.
 Buckley JD1, Meadows AT, Kadin ME, et al. Pesticide exposures in children with non-Hodgkin lymphoma. Cancer. 2000 Dec 1;89(11):2315-21.
 Kokouva M1, Koureas M, Dardiotis E, et al. Relationship between the paraoxonase 1 (PON1) M55L and Q192R polymorphisms and lymphohaematopoietic cancers in a Greek agricultural population. Toxicology. 2013 May 10;307:12-6. doi: 10.1016/j.tox.2012.07.003. Epub 2012 Jul 16.
 Fallah M1, Liu X2, Ji J2, Försti A3, et al. Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study. Ann Oncol. 2014 Jul 31. pii: mdu365. [Epub ahead of print]
 Cohen L1, Warneke C, Fouladi RT, et al. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer. 2004 May 15;100(10):2253-60.
 Teras LR, Gapstur SM, Diver WR, Birmann BM, Patel AV. Recreational physical activity, leisure sitting time and risk of non-Hodgkin lymphoid neoplasms in the American Cancer Society Cancer Prevention Study II Cohort. Int J Cancer. 2012 Oct 15;131(8):1912-20. doi: 10.1002/ijc.27445. Epub 2012 Mar 8.